Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim for Adult Severe Aplastic Anemia: Bridging Study in IST-naive and IST-refractory Patients
jRCT2031230178Completed
- Sponsor
- Amgen
- Start
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of romiplostim in aplastic anemia (2 arms), sponsored by Amgen. Primary endpoint: Any hematologic response at week 14 (Arms 1 and 2). Started Aug 2023; status: completed.
02
Drugs
romiplostim
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on jRCT2031230178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230178.